Literature DB >> 10228034

Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta.

K C Fang1, P J Wolters, M Steinhoff, A Bidgol, J L Blount, G H Caughey.   

Abstract

Our prior work shows that cultured BR cells derived from dog mastocytomas secrete the 92-kDa proenzyme form of gelatinase B. We provided a possible link between mast cell activation and metalloproteinase-mediated matrix degradation by demonstrating that alpha-chymase, a serine protease released from secretory granules by degranulating mast cells, converts progelatinase B to an enzymatically active form. The current work shows that these cells also secrete gelatinase A. Furthermore, gelatinases A and B both colocalize to alpha-chymase-expressing cells of canine airway, suggesting that normal mast cells are a source of gelatinases in the lung. In BR cells, gelatinase B and alpha-chymase expression are regulated, whereas gelatinase A expression is constitutive. Progelatinase B mRNA and enzyme expression are strongly induced by the critical mast cell growth factor, kit ligand, which is produced by fibroblasts and other stromal cells. Induction of progelatinase B is blocked by U-73122, Ro31-8220, and thapsigargin, implicating phospholipase C, protein kinase C, and Ca2+, respectively, in the kit ligand effect. The profibrotic cytokine TGF-beta virtually abolishes the gelatinase B mRNA signal and also attenuates kit ligand-mediated induction of gelatinase B expression, suggesting that an excess of TGF-beta in inflamed or injured tissues may alter mast cell expression of gelatinase B, which is implicated in extracellular matrix degradation, angiogenesis, and apoptosis. In summary, these data provide the first evidence that normal mast cells express gelatinases A and B and suggest pathways by which their regulated expression by mast cells can influence matrix remodeling and fibrosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10228034

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  29 in total

Review 1.  Importance of mast cells in the pathophysiology of asthma.

Authors:  Seong H Cho; Andrea J Anderson; Chad K Oh
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

2.  AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.

Authors:  Tzu-Yin Lin; Joelle Fenger; Sridhar Murahari; Misty D Bear; Samuel K Kulp; Dasheng Wang; Ching-Shih Chen; William C Kisseberth; Cheryl A London
Journal:  Blood       Date:  2010-03-16       Impact factor: 22.113

Review 3.  Control of matrix metalloproteinase catalytic activity.

Authors:  Hyun-Jeong Ra; William C Parks
Journal:  Matrix Biol       Date:  2007-07-07       Impact factor: 11.583

Review 4.  Mast cells as early responders in the regulation of acute blood-brain barrier changes after cerebral ischemia and hemorrhage.

Authors:  Perttu Johannes Lindsberg; Daniel Strbian; Marja-Liisa Karjalainen-Lindsberg
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

Review 5.  Mast cell proteases as pharmacological targets.

Authors:  George H Caughey
Journal:  Eur J Pharmacol       Date:  2015-05-07       Impact factor: 4.432

6.  Early neoplastic progression is complement independent.

Authors:  Karin E de Visser; Lidiya V Korets; Lisa M Coussens
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

Review 7.  Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation.

Authors:  Steven Maltby; Khashayarsha Khazaie; Kelly M McNagny
Journal:  Biochim Biophys Acta       Date:  2009-02-21

Review 8.  The immune system and cardiac repair.

Authors:  Nikolaos G Frangogiannis
Journal:  Pharmacol Res       Date:  2008-06-24       Impact factor: 7.658

9.  Mast cells are an essential hematopoietic component for polyp development.

Authors:  Elias Gounaris; Susan E Erdman; Clifford Restaino; Michael F Gurish; Daniel S Friend; Fotini Gounari; David M Lee; Guoying Zhang; Jonathan N Glickman; Kichul Shin; Varada P Rao; Theofilos Poutahidis; Ralph Weissleder; Kelly M McNagny; Khashayarsha Khazaie
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-06       Impact factor: 11.205

10.  Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease.

Authors:  L Wu; J Chau; R P Young; V Pokorny; G D Mills; R Hopkins; L McLean; P N Black
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.